BMO Capital Starts Ra Pharma (RARX) at Outperform

BMO Capital initiates coverage on Ra Pharma (NASDAQ: RARX) with a Outperform rating and a price target of $26.00.

Analyst M. Ian Somaiya commented, " RARX offers investors de-risked access to the multi-billion-dollar complement space, which we believe ALXN has left open to competition. Ra Pharma’s lead drug, RA101495, is a peptide against complement C5. We expect convenience of a daily (potentially weekly) subcutaneous administration to enable ‘1495 to be the preferred drug in PNH patients who are experiencing breakthrough hemolysis on Alexion’s Soliris and take ~15% of refractory MG market, supporting peak sales of $2.7bn and our Outperform rating. We do not model any contribution from RARX's complement pipeline or Merck partnership."

For an analyst ratings summary and ratings history on Ra Pharma click here. For more ratings news on Ra Pharma click here.

Shares of Ra Pharma closed at $13.29 yesterday.

You May Also Be Interested In